High Throughput RNA Sequencing of Mice Retina Reveals Metabolic Pathways Involved in the Gut-Retina Axis

Urooba Nadeem[1], Bingqing Xie[2,3], Asadolah Movahedan[4], Mark D'Souza[2], Hugo Barba [5], Nini Deng[6], Vanessa A. Leone[7], Eugene Chang[8], Dinanath Sulakhe[3], Dimitra Skondra[5]

1. Department of Pathology, University of Chicago, Chicago, Illinois, USA
2. Center for Research Informatics, The University of Chicago, Chicago, IL, USA
3. Department of Medicine, University of Chicago, IL, USA
4. Department of Ophthalmology and Visual Science, Yale University School of Medicine, New Haven, CT, USA
5. Department of Ophthalmology and Visual Science, University of Chicago, Chicago, IL, USA
6. Department of Ophthalmology, Aier Eye Hospital Group Co. Ltd. NanNing 530000, Guangxi Zhuang Autonomous Region, China
7. Department of Animal & Dairy Sciences, University of Wisconsin-Madison, Madison, WI 53706
8. Department of Medicine, Microbiome Medicine Program, Knapp Center for Biomedical Discovery, University of Chicago, Chicago, IL 60637

Corresponding Author: Dimitra Skondra MD, PhD
Email: dskondra@bsd.uchicago.edu

Contact Info:

Address: 5841 S. Maryland Avenue, S426m MC2114, Chicago, IL, 60637, USA

[Office]: 773.702.3937

[Fax]: 773.702.0830

Funding: Bright Focus DS, ISPB AM, DS, Women's Board [DS], NIDDK P30 DK42086
Financial Disclosures: Urooba Nadeem: None relevant to this study, Hugo Barba: None relevant to this study, Bingqing Xie: None relevant to this study, Mark D'Souza: None relevant to this study, Asad Movahedan: None relevant to this study, Nini Deng**:** Aier Eye Hospital Group Youth Fund Project **-** Mutation screening of pathogenic genes for high myopia using Sanger sequencing technology [not relevant to this study], Vanesssa Leone: None relevant to this study, Dinanath Sulakhe: Co-founder at Navipoint Genomics LLC and Navipoint Health Inc [not relevant to this study], Eugene Chang: None relevant to this study, Dimitra Skondra: Consultant to Allergan, Biogen and Alimera, Scientific Advancement Board (not relevant to this study)

Acknowledgments: We thank University of Chicago Core Genomic team, Peter Fabier and Mikayla Marchuk, for helping with RNA sequencing. Gnotobiotic Research Animal Facility (GRAF) staff (Betty Theriault and Melanie Spedale) and Donna Arvans for care of the germ-free animals and Chang lab members Candace Cham, Xiaorong Zhu, Jason Koval and Amal Kambal.

Abstract

Background and aims:

Connections between the gut microbiome and retinal diseases such as age-related macular degeneration (AMD), diabetic retinopathy (DR), retinopathy of prematurity (ROP), and primary open-angle glaucoma (POAG) are recently being established. Communication between the gut microbiome and retina, referred to as the gut-retina axis, has been proposed; however, the biologic pathways and mediators involved in the interactions have not yet been elucidated. Using high-throughput RNA sequencing (RNA-seq) of whole retinas, we compare the retinal transcriptome from germ-free (GF) and specific pathogen-free (SPF) mice to investigate effects of the gut-microbiome on both retinal gene expression and biologic pathways.

Methods:

RNA was extracted from whole retinas of GF and SPF mice (four animals per group) and cDNA libraries were created. RNA-seq was performed on NovaSEQ6000 using the paired-end method. After preprocessing the RNA-seq data, gene expression value was calculated by count per million (CPM). The differentially expressed genes (DEGs) were identified with edgeR Bioconductor analysis of expression data. Functional enrichment and protein-protein interaction (PPI) network analyses were created for the differentially expressed genes (DEGs).

Results:

RNA-sequencing reveals a cohort of 396 DEGs, of which, 173 are upregulated and 223 are downregulated in GF mouse retina. Enrichment analysis reveals that the DEGs are involved in glucocorticoid effects, transcription factor binding, cytoskeletal stability, lipid metabolism, and mitogen-activated protein kinase (MAPK). Multiple biologic pathways, including obesity/metabolic syndrome, longevity, and 5' AMP-activated protein kinase (AMPK) signaling pathway are affected in the GF retinas. PPARG1a (PGC1a) gene is involved in 12 of the 16 significantly modulated pathways. Proteins with the most number of interactions in the PPI are E1A binding protein P300(EP300), forkhead box O3(FOXO3) and PGC1a.

Conclusions:

To our knowledge, this is the first study demonstrating the involvement of the gut microbiome in driving the retinal transcriptome, providing evidence for the presence of a gut-retina axis. Future studies are needed to define the precise role of the gut-retina axis in the pathogenesis of retinal diseases.

Keywords (according to MeSH)

Gut-retina axis; transcriptome; high-throughput RNA-sequencing; germ-free mouse; gut microbiome; age-related macular degeneration; diabetic retinopathy; primary open angle glaucoma

Introduction

The gut microbiome is the collective microbiota and their genetic material residing symbiotically in the gut. [1] Effects of the gut microbiome in diseases of anatomically distant sites, for instance, skeletal muscle, lung, and brain, are well-recognized. [2,3] However, its role in ocular conditions, especially retinal diseases is only recently being recognized. [4,5] Communication between the gut microbiome and retina, also referred to as the gut-retina axis has been proposed; but to date, the biologic mediators and pathways affected in the retina by the gut microbiome are not known.

The concept of the gut microbiome affecting anatomically distant organs, especially the regulation at an immune-privileged site, like the eye, is very perplexing. [6] In the past few years, data for the gut microbiome's involvement in retinal diseases is accumulating. [7,8] Autoimmune uveitis was the first ocular disease linked with an altered gut microbiome. [9] Early microbiome studies show germ-free (GF) mice completely devoid of microbiota, have a modified retinal lipidome. [10] Huihui Chen *et al.* showed that GF mice relative to mice with an intact microbiome are protected from glaucoma by a T-cell mediated effect. [11] Alteration of the microbiome by diet (also known as gut dysbiosis) illustrates that high-sugar and fat diets exacerbate worsened features of dry age-related macular degeneration (dAMD) and neovascular AMD, respectively. [4,12,13] On the other hand, it is shown that restricting the gut microbiome by fasting prevents diabetic retinopathy (DR) and prolongs survival in mice. [14] Human studies have determined that the gut microbiome is compositionally and functionally different in wet AMD, [14] primary open-angle glaucoma (POAG), [15] retinal artery occlusion (RAO) [17] and retinopathy of prematurity (ROP) [18] in contrast to healthy subjects. Gut microbiota modulation may serve as a novel strategy for the prevention and treatment of retinal diseases.

A recent study shows that remodeling the gut-microbiome has a favorable influence on retinal morphology and decreases age-related retinal ganglion cell (RGC) loss. [19] Another investigation suggests that administration of probiotics may modulate clinical signs of autoimmunity in the eye. [20] Andriessen et al show the gut microbiota influences the development of neovascular lesions associated with AMD and modifying microbiota can decrease systemic and local chorioretinal inflammation, subsequently decreasing pathological choroidal neovascularization. [12] Despite this knowledge, the gut microbiome's precise role in retinal disease pathogenesis remains unknown; nonetheless, the functional differences between health and disease states support the presence of a gut-retina axis.

Multiple animal models have been used to study the microbiome, using antibiotics and diet to modulate the microbiome are the most common methods for these studies. [4, 12] Nevertheless, these models do not allow for assessing changes caused by antibiotics and diet, as opposed to the effects caused by the microbiome alone. [21] 16S rRNA gene sequencing can be used to compare taxonomic differences between gut microbes of patients and healthy controls. [22] All these techniques provide significant primary evidence for linking the gut-microbiome to the retinal

diseases; but, to move beyond the correlation phase of experiments; preclinical mouse models are essential. [21,23] The GF mouse model is considered the gold-standard for proof-of-concept microbiome investigations and has been used in milestone discoveries to determine causal links between the microbiome and disease. [24,25,26] Presently, no studies use the GF mouse model to describe the gut microbiome's role in the gut-retina axis.

Here, we profiled the retinal transcriptome to identify differentially expressed genes (DEG) between GF and specific pathogen-free (SPF) mice retina; the latter serving as a control group. Advances in high throughput RNA-sequencing and computational bioinformatics analysis have evolved as powerful methods to yield detailed information on novel genes and pathways involved in different conditions. [27] The study design is illustrated in Figure 1. To our knowledge, no microbiome studies have illustrated alterations in the retinal transcriptome utilizing RNA-seq technology. We identified DEGs between the two groups revealing dysfunctional biological processes (BPs), molecular functions, cell components, and pathways. Furthermore, protein-protein interactions (PPIs) of the DEGs are also explored.

Changes in gene expression by modulating the gut-microbiome have already been established in the GI tract, [28] skeletal muscle, [29] and the liver. [30] We show that similarly the gut microbiome can also modulate gene expression in the retina. Our study provides a global insight into the retinal genes and pathways influenced by the gut microbiome. Future investigations are needed to elucidate the function of the microbiome in specific retinal diseases, which can aid in developments in alternate or adjunct prevention strategies and therapies for medically refractory and incurable retinal diseases.

Figure1. Schematic diagram illustrating the experiment methodology

Materials and Methods

Animals

All experiments were performed per-the Association for Research in Vision and Ophthalmology (ARVO) statement for the use of animals in Ophthalmic and Vision Research and were institutionally approved. Adult male mice C57Bl/6 mice were utilized for this study. The GF mice were bred in the Gnotobiotic Research Animal Facility (GRAF) at the University of Chicago (U of C). SPF mice were purchased from the Jackson Laboratories and bred in at the Animal Resources Center (ARC) at the U of C SPF animal vivarium. SPF mice were kept in sealed cages in a ventilated rack system.

Mice were fed normal rodent chow. Food and water were provided *ad libitum* to both groups and they are exposed to 12:12 light: dark cycle. The environmental parameters of temperature and humidity were kept within the range required by The Guide for the Care and Use of Laboratory Animals, Eighth Edition. [31] At 15 weeks of age, the mice were sacrificed via CO_2 asphyxiation followed by cervical dislocation. All measures were taken to minimize stress and pain throughout the procedure. Sample processing for this experiment was immediately started on ice as an extra cautionary measure to prevent biologic/ genetic material contamination and degradation.

Sterility Monitoring

To ensure sterility in GF mice, they were housed, bred, and maintained in a sterile flexible film isolator at the U of C GRAF. Diets for GF mice were autoclaved (250 F, 30 minutes). Weekly fecal pellets were collected for sterility monitoring via microbial cultures, as previously described. [32] No positive cultures were identified in any of the GF mice used in this study.

RNA extraction

After the mice were sacrificed, eyes were enucleated and carefully dissected and the retinas were extracted on ice using sterile technique. All surfaces, tools, tubes, and equipment were treated with RNase decontamination solution (RNaseZAP, Thermofisher Scientific Waltham, MA). The retinas were immediately stored in RNA*later* (Qiagen, Germantown, MD) in RNase free Eppendorf tubes and stored at -80C until RNA extraction. For the mRNA extraction, the RNeasy (Qiagen, Germantown, MD) was used. Each sample was analyzed using Nanodrop (NanoDrop 2000cc, Thermo Scientific, Waltham, MA) to determine total RNA concentration before sequencing.

RNA sequencing

Eight samples of purified RNA (4 from each group) were used for this analysis. Before sequencing, the RNA quality was assessed via the Bioanalyzer and the samples were confirmed to have the required RNA integrity numbers (RIN) concentration (both done at U of C Genomics core). The cDNA library of each sample was prepared using Tru-Seq RNA Sample Prep Kits (Illumina, San Diego, CA) for 100 bp paired-end reads, according to the manufacturer's instructions. Each of the eight cDNA libraries was indexed for multiplexing. These indexed

libraries were sequenced on NovaSEQ6000 (Illumina, San Diego, CA) using PE100bp. Data were recorded in the FASTQ format and then imported in R for bioinformatics analysis.

Statistical Analysis

The secondary analysis of sequence data was performed on Globus Genomics,[33] an enhanced, cloud-based analytical platform that provides access to different versions of Next-Generation Sequence analysis tools and workflow capabilities. Tools such as STAR[34], featureCounts,[35] and Limma were run from within the Globus Genomics platform. We used STAR (version 2.4.2a, Stanford University, CA) aligner default parameters to align the RNA-seq reads to the reference mouse genome (GRCm38) for all the eight samples. The raw gene expression count matrix was then generated by featureCounts (version subread-1.4.6-p1). [35] The gene annotation was obtained from the Gencode vM23.[37] STAR default parameter for the maximum mismatches is 10 which is optimized based on mammalian genomes and recent RNA-seq data.

We obtained a matrix with 55213 genes and eight samples as the final output. The data was imported to R for downstream analysis. The raw gene count matrix for all samples was transformed into log-CPM (count per million) values. Genes without sufficiently large counts were filtered using EdgeR Bioconductor. [38] 20,287 genes were selected for the downstream analysis. We used Limma Voom [39] normalization to standardize the gene expression matrix, where the raw library sizes were scaled using TMM (trimmed mean of M values). Multidimensional scale plots were generated on top 6 leading FC dimensions which showed the similarity between samples.

The differential expression analysis was performed on contrast group SPF against GF using Limma. [40] Significant DEGs with p-value < 0.05 were extracted for further downstream analysis. The enrichment analysis in Toppgene suite took both the upregulated and downregulated DEGs in GF and extracted the over-represented gene ontology functional classification (molecular functions, biological processes, and cellular component). [41] The significance of the association between the datasets and bio functions were measured using a ratio of the number of genes from the dataset that map to the pathway divided by the total number of genes in that pathway. This enrichment analysis was based on mouse-to-human orthologs. A list of all DEGs and their p-values is available in Supplementary Table 1.

Proteins are known to work together to exert a specific function. Therefore, we mapped the identified DEGs into the STRING (Search Tool for the Retrieval of Interacting Genes) database (http://string-db.org/), which contains a wealth of validated and text mined PPIs among the proteins, to further explore the relationships of these DEGs from protein level.[42] We used the DEGs (p-value < 0.05) to identify PPI for both the upregulated and downregulated genes in GF mice.

Results

Gut microbiome modifies global retinal gene expression

To compare the retinal transcriptome profile of SPF vs.GF mice, we performed high throughput RNA-seq analysis of mouse retinas from the two groups. To obtain precise results, four separate retinas were obtained from each sample group (biological replicates). After the correction of the

raw data to remove background noise, 20,287 genes were selected for differential gene analysis. DEGs were labeled as the genes with a p-value of <0.05. A comparison between the two groups revealed that 396 DEGs were identified, 173 upregulated and 223 downregulated genes in the GF mice group. Using the criteria of log fold-change ($\log_2$FC)>1, we performed an unsupervised analysis of these DEGs. This revealed 60 genes; 40 upregulated and 20 downregulated in the GF mice retina. Heatmap are plotted to show the hierarchical clustering of these genes (Figure 2). The volcano plot demonstrates a distinct retinal gene expression in retinas from SPF vs GF mice (Figure 2). Our data support s that there are substantial differences in the global gene expression in GF and SPF retina; hence, supporting the presence of gut-retina axis. Detailed statistics of the DEGs are available in Supplementary Table 1.

Figure2. Comparing the gene expression profiles of the GF and SPF mice
 (A). Hierarchical clustering of retinal genes of GF vs SPF mice demonstrated by the heatmap. Red and yellow indicate upregulated and downregulated genes in the GF mice retina, respectively. DEGs with log2FC > 1 (more than 2-fold difference) are included in this heatmap. (B). Volcano plot showing DEGs in GF vs SPF mice shows a distinctive gene expression profile of two groups with minimal overlap. X-axis represents log2 FC and the Y-axis represents -log10 (P-values). (DS01, DS02, DS03, DS04- SPF and DS09, D10, DS11, DS12- GF)

Enrichment Analysis reveals Gut Microbiome Regulates Multiple Key Biological Pathways in Mouse Retina

The enrichment analysis for both Gene Ontology and pathways was performed using Toppgene [41]. The genes were mapped from mouse ortholog. The enrichment analysis identifies significantly over-represented gene ontology functional categories (Figure 3) and pathways based on DEG (Figure 4). The analysis revealed that the DEGs are involved in glucocorticoid receptor binding (GO:0035259), steroid hormone effects (GO:0071383), transcription factor binding (GO:0008134), cytoskeletal stability (GO:0007010), lipid metabolism (GO:0071396) and mitogen-activated protein kinase (MAPK) activity (GO:0017017).

	Name	Source	p-Value	Number of Genes affected from dataset
1	GO:0033043	regulation of organelle organization	6.379E-7	34
2	GO:0051493	regulation of cytoskeleton organization	4.160E-6	19
3	GO:0007010	cytoskeleton organization	4.804E-6	36
4	GO:0046831	regulation of RNA export from nucleus	1.112E-5	4

5	GO:0071383	cellular response to steroid hormone stimulus	1.185E-5	12
6	GO:1901880	negative regulation of protein depolymerization	1.335E-5	7
7	GO:0014070	response to organic cyclic compound	1.646E-5	26
8	GO:0032239	regulation of nucleobase-containing compound transport	1.910E-5	4
9	GO:0071396	cellular response to lipid	2.414E-5	19
10	GO:1902903	regulation of supramolecular fiber organization	2.450E-5	14

Significant Terms For: GO: Biological Process

	Name	Source	p-Value	Number of Genes affected from dataset
1	GO:0035259	glucocorticoid receptor binding	5.673E-5	4
2	GO:0019900	kinase binding	8.485E-5	23
3	GO:0003682	chromatin binding	9.231E-5	18
4	GO:0008134	transcription factor binding	9.808E-5	20
5	GO:0017017	MAP kinase tyrosine/serine/threonine phosphatase activity	2.844E-4	3
6	GO:0051427	hormone receptor binding	3.017E-4	9
7	GO:0033613	activating transcription factor binding	3.548E-4	6
8	GO:0019901	protein kinase binding	3.832E-4	20
9	GO:0033549	MAP kinase phosphatase activity	4.456E-4	3
10	GO:0043495	protein-membrane adaptor activity	4.456E-4	3

	Name	Source	p-Value	Number of Genes affected from dataset
1	GO:0016604	nuclear body	8.093E-7	24
2	GO:0015630	microtubule cytoskeleton	5.018E-5	29
3	GO:0036477	somatodendritic compartment	1.459E-4	24

Figure 3A, B, C. Table for top 10 biologic processes, molecular function and cell component revealed by enrichment analysis in the DEGs. Corresponding bar-charts show the genes affected

in our dataset compared to the total number of genes involved in the condition. The figure is made using Toppgene.

The absence of the gut microbiome influenced sixteen biologic pathways in the GF retina (Figure 4). All these pathways are downregulated in the GF mice retina compared to the SPF group. These pathways were involved in obesity/metabolic syndrome, adenosine monophosphate-activated protein kinase (AMPK), nuclear SMAD 2/3 signaling, mitochondrial biogenesis, lipid metabolism, longevity, and oxidative stress response, which are already known to be crucial in the pathogenesis of numerous retinal diseases. However, novel pathways with no known function in retinal diseases, but demonstrated to be regulated by the gut-microbiome, for example, intraflagellar transport, and the circadian clock, are also shown to be affected by the gut microbiome. Our data shows that the DEGs in the modified pathways have considerable overlap (Figure 4). PPARGC1A (now referred to as PGC-1α) is involved in twelve of the sixteen pathways and seems to be especially important.

Pathway	P-value	Number of Genes involved from the dataset
Obesity / Metabolic Syndrome	1.90E-06	PPARGC1A,NCOA2,NR3C1,EP300
Regulation of nuclear SMAD2/3 signaling	2.42E-06	MEF2C,NCOA2,FOXO3,SIN3A,NR3C1,ATF2,EP300,SMAD7
Circadian Clock	1.50E-05	NRIP1,MEF2C,PPARGC1A,NCOA2,NR3C1,ATF2,EP300
ATF-2 transcription factor network	3.48E-05	PPARGC1A,CUL3,DUSP5,DUSP8,ATF2,EP300
Longevity regulating pathway	6.54E-05	PPARGC1A,KL,PIK3CB,RPTOR,FOXO3,ATF2,ADIPOR1
Intraflagellar transport	9.37E-05	TTC26,WDR35,TNPO1,WDR19,DYNC2LI1
RAF-independent MAPK1/3 activation	1.18E-04	JAK1,DUSP5,DUSP7,DUSP8
Transcriptional activation of mitochondrial biogenesis	1.47E-04	MEF2C,PPARGC1A,NCOA2,ATF2,ATP5F1B
Oxidative stress response	1.64E-04	MEF2C,DUSP5,DUSP7,DUSP8,ATF2
BMAL1:CLOCK,NPAS2 activates circadian gene expression	2.01E-04	NRIP1,PPARGC1A,NCOA2,NR3C1,EP300
Mitochondrial biogenesis	3.51E-04	MEF2C,PPARGC1A,NCOA2,ATF2,ATP5F1B
AMPK signaling pathway	4.44E-04	ACACA,PPARGC1A,PIK3CB,RPTOR,FOXO3,PPP2R3A,ADIPOR1
RORA activates gene expression	2.61E-04	NRIP1,PPARGC1A,NCOA2,EP300
Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha)	4.91E-04	NRIP1,ME1,CITED2,PPARGC1A,EP300

Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)	5.94E-04	ME1,PPARGC1A,NCOA2,SIN3A,MED13L,MED19,EP300
CARM1 and Regulation of the Estrogen Receptor	6.28E-04	NRIP1,MEF2C,PPARGC1A,EP300

Figure 4: The pathways downregulated by the DEGs revealed by enrichment analysis. Corresponding bar-charts showing the genes affected in our dataset compared to the total number of genes involved in the GF mice. The figures are made using Toppgene.
Figure 4b. Select pathways and their corresponding involved genes revealed by enrichment analysis. The downregulated pathway is in the middle of the figure. Genes involved in multiple pathways are represented on both the left and right of the figure.

Protein-Protein interactions
Using the STRING database with both the upregulated and downregulated DEGs in the GF retina groups, PPI analysis was done. In the PPI network, a node represents a protein and the degree of a node represents the number of the interplayed pairs with other proteins of this specific node. The proteins which are the predominant nodes with a high degree of connections to other proteins (hub nodes) include histone acetyltransferase p300 (EP300), PGC1a, and forkhead box O3 (FOXO3) in the analysis conducted on the DEGs downregulated in the GF mice. The PPI constructed from the DEGs upregulated genes is sparser and more disconnected, as would be expected from the earlier enrichment analysis (Fig. 5). The pathway analysis of the downregulated proteins GF retina shows that they are involved in are AMPK and longevity (Supplementary table 2).

Figure 5. String networks of protein-protein interaction (PPI) generated using DEGs (p-value < 0.05). A. Shows the proteins that were involved in the downregulated genes in the GF mice B. Figure shows the network of the proteins downregulated in GF mice

Discussion

In this study, we used high throughput RNA sequencing to compare the entire retinal transcriptome of whole retinas from GF and SPF mice. Our results show that retinal gene expression is altered by the gut-microbiome the presence of gut microbiotas. 396 DEGs (p-value <0.05) are identified between the two groups. Functional categories the DEGs belong to include glucocorticoid receptor binding, steroid hormone response, lipid metabolism, and transcription factor binding. Additional genes involved in cytoskeletal stability and regulation of T-helper-17 (Th17) differentiation are also affected. Analysis of the DEGs shows pathways affected by the gut-microbiome are obesity/metabolic syndrome, MAPK, mitochondrial biogenesis, longevity, AMPK, and oxidative stress (Figure 4). Molecules proved shown to be regulated by the gut-microbiome in the gastrointestinal tract like tissue metallopeptidase inhibitor 4 [43] and mucin 2 [44] are also affected in the GF mice retina. Hub nodes in the downregulated PPI network include PGC1a, EP300, and FOXO3; all of which are involved in the pathogenesis of retinal diseases. Notably, the pathways downregulated in GF retina protein analysis are AMPK and longevity pathways, further confirming that these pathways are indeed influenced in the retina by gut microbial status.

We hypothesized that the gut microbiome regulates retinal function by modifying retinal gene expression. To test the hypothesis, we use GF mice which are considered the gold standard for proof-of-concept questions for microbiome studies. As discussed above, the GF mice are important for demonstrating correlative relationships. [21,22,25] They have proved invaluable for establishing causal links between the microbiome and diverse diseases such as inflammatory bowel disease, cancers, autoimmune conditions, and neurologic conditions. [45,46] Recent evidence highlights the importance of the gut microbiota in modulating response to different cancer immunotherapy drugs. [47] Methods for studying the microbiome include microbiota inhibition using antibiotics, diet alteration to cause gut dysbiosis (changes microbial

composition), and the introduction of microbial strains directly into animals that have conventional microbiota. [48] Modulating the microbiome through diet and/or antibiotics is relatively easier, cheaper, and does not require specialized facilities compared to the GF mice. Nonetheless, using antibiotics has limitations, including off-target drug effects, only partial ablation of microbes, possible selection of resistant strains, and direct influence of the drug on the genetic and metabolic machinery of host tissue [48]. Dietary manipulation results in alteration of the microbiota; however, a high-fat diet may cause obesity regardless of the composition of gut microbiota in mice. [49] Therefore, in addition to the indirect dietary influence caused by dysbiosis, it is likely that there is a direct impact of the dietary constituents on the host tissue. Introducing microbial strains by fecal transplant has revealed to be beneficial in ocular surface conditions, e.g. it shows an improved goblet cell density, decreased corneal barrier disruption, and dacryoadenitis in animal models of Sjogren's syndrome. However, only very limited studies comparable investigations have been attempted for retinal diseases. Host-microbe interactions can be studied more accurately and precisely without the background noise from a preexisting microbiome in the GF mice. [21,22] Hence, we chose GF mice to identify genes and pathways involved in the gut-retina axis. To our knowledge, this is the first report using GF mice to outline the transcriptomic changes in the retina caused by changes in the gut microbiome.

As mentioned earlier, there are compositional and functional differences in the enteric microbiome in AMD, POAG, RAO, and ROP patients. Investigators are trying to comprehend how different species of microbiota contribute to genomic changes in the host. Numerous theories have been proposed; the most accepted are the downstream impact from the metabolites produced from the microbiota. Taylor *et al*. show that modifying the gut-microbiome by a high-glycemic-index diet leads to retinal damage; they use metabolomics to compare the severity of the retinal damage with multiple microbial metabolites.[4] Other studies show the protective nature of the gut microbiota metabolites in the retina; exogenous short-chain fatty acids (SCFA) decreases autoimmune uveitis,[50] ursodeoxycholic acid (UDCA) ameliorates DR [51] and tauroursodeoxycholic acid (TUDCA) protects against cell death in retinal degeneration, [52,53] retinal detachment,[54] and protects neural retina in the diabetic mouse model.[55] Further credence is provided to this theory by the presence of SCFA transporters, sodium-coupled monocarboxylate transporter 1 and 2 (SMCT1 and SMCT2), and receptor G protein-coupled receptor 109A (GPR109A) in the retina.[56] Our data shows that SMCT2 (SLC5A12) gene is upregulated in GF mice (Supplementary Table 1). Another recent study shows that modifying the gut microbiome by feeding mice *L.paracasei KW3110* demonstrates favorable changes in retinal function and morphology on the aging retina.[19] These studies lay the groundwork for the connection between the enteric microbiome and the retina; however, these investigations did not reveal if the microbiota or its their metabolites may alter the retinal gene expression. RNA-seq is a revolutionary technique that can generate very precise results to study the entire transcriptome of the tissue. In our study, we used high throughput RNA-seq to evaluate the retinal transcriptome of GF mice retina. We generated a detailed view of the genes and pathways affected in the retina by the gut microbiome but further studies are required regarding the mechanism by which gut microbiota regulates the retinal gene expression as seen in our studies.

The importance of DEGs in retinal diseases including AMD, POAG, and DR (Figure 6) is well-recognized. The most influenced gene in our data is the transcriptional coactivator PGC-1α, which is affected in 12 of the 16 altered pathways (figure 4B). This gene is involved in numerous

retinal diseases. Zhang *et. al* show that AMPK/PGC-1α pathway is dysfunctional in AMD patients. They show that alteration of this pathway leads to increased intracellular accumulation of lipids and cellular waste, decreased mitochondrial biogenesis and turnover, and subsequent mitochondrial dysfunction.[57] Our data shows both PGC-1α and AMPK pathways are differentially expressed in the GF mice retina, indicating that the gut microbiome is involved in the regulation of this pathway in the retina. Additional enrichment analysis reveals genes involved in downstream activities of AMPK/PGC-1α including lipid metabolism and mitochondrial biogenesis are also influenced (Figure 5). AMD is a heterogeneous disease with a very unpredictable course; if the differences in gut-microbiome cause AMPK/PGC-1α dysregulation and explain this heterogeneity in different patients remains to be seen. PGC-1α is also the major transcriptional coactivator for steroid hormone receptors and its nuclear receptors. Expectedly, glucocorticoid receptor binding and cellular effects of steroids are among the top ten dysfunctional molecular functions and biologic processes affected in GF mice (Figure 3). We show for the first time that and PGC-1α- steroid pathways are both modified in the retina through the gut-microbiome. However, further studies of protein expression and hormone activity are needed to determine the microbiome's influence on PGC-1α protein in models of specific retinal diseases.

AMPK can function through genes other than the PGC-1A. One of these principal pathways is the mammalian target of rapamycin (mTOR); RPTOR (Regulatory Associated Protein of MTOR Complex 1), the central gene of the mTOR pathway is downregulated in GF mice retina. mTOR activates protein and lipid anabolism and inhibits autophagy. Overactivity of mTOR has been shown in AMD,[57] glaucoma [58], and diabetic retinopathy. In DR, VEGF synthesis is stimulated via the mTOR pathway which leads to activation of downstream signaling cascade including AMPK and increased angiogenesis and blood-retinal barrier (BRB) breakdown. [59] The activation of AMPK leads to further activation of mTOR forming an activation loop. The bidirectional cross-talk between the microbiome and mTOR is through microbial metabolites, SCFA, and (trans-10, cis-12 conjugated linoleic acid (t10, c12 CLA). Reciprocally, the mTOR pathway influences the composition of gut microbiota by controlling gut barrier function. Interestingly, genes maintaining the retinal-blood barrier, like Elovl and Slc16a1 are also downregulated in GF mice. The concept of a leaky gut syndrome or increased intestinal permeability based on variations in the microbiome has been accepted. [60] This concept has also been extrapolated to the blood-brain barrier; based on our data, we propose that the enteric microbiome may regulate the permeability of the retinal blood-brain barrier.

The most impacted pathway in the GF retina is the obesity/metabolic syndrome (Figure 4). The genes involved are PGC1α, nuclear receptor coactivator 2(NCOA2), nuclear receptor subfamily 3 group C member 1(NR3C1), and EP300. The proteins for these genes also appear to have a prominent position in the PPI, and both PGC1α and EP300 are major hub nodes in the downregulated genes in GF mice (Figure 5). All these genes and their proteins have a prominent function in the steroid hormone metabolism. EP300 is crucial for retinal biology; it is a co-activator of hypoxia-inducible factor 1 alpha (HIF-1A)and stimulates the hypoxia-induced genes such as vascular endothelial growth factor (VEGF).[61] VEGF is the major angiogenic factor involved in AMD. [62,63,64,65,66] Anti-VEGF injections inhibit angiogenesis in neovascular AMD, DR, and retinal vein occlusion (RVO). Our data shows that the EP300-HIF-1-VEGF pathway is downregulated in the GF mice retina which suggests that microbiome modulates the

expression of angiogenesis-related genes and pathways in the retina. [67] Hence, the gut-microbiome may be of worthy consideration in pathogenesis of retinal diseases with pathologic neovascularization. These findings support the involvement of the gut microbiome in disease development and progression; but, precise future studies are needed to determine the exact gut microbiome-retinal angiogenesis pathway.

Another downregulated pathway in the GF retina is the Smad2/3 signaling pathway. The Smad signaling pathway is synergistic with the MAPK. MAPK phosphorylates multiple transcription factors, including c-Jun and ATF-2 and Smad proteins. Phosphorylation by MAPK pathways results in subsequent activation of their transcriptional activity. Predictably, each of these transcription factor genes and MAPK are downregulated in GF retina. There is crosstalk between MAPK signaling and several different pathways, such as VEGF and oxidative stress. [68] Oxidative stress via reactive oxygen species (ROS) serves as an important signal that activates MAPK signaling, which is also dysregulated in the GF eyes. MAPK activation has been implicated in the pathogenesis of several retinal diseases including AMD and DR. However, despite this, several ocular MAPK inhibitors have failed to produce desired outcomes in retinal diseases; in fact, MAPK drugs for tumors may have serious ocular side effects. [69] Given our data, the regulation of MAPK via the gut-microbiome may serve as a probable target for intervention in retinal diseases.

A recent study shows melatonin inhibits inflammation and apoptosis in animals with DR via the MAPK pathway. [70] A separate study shows that the gut microbiota is sensitive to melatonin and expresses endogenous circadian rhythmicity. [71] Our study supports that several retinal genes of the circadian rhythm clock are affected by the gut microbiome. The mammalian retina contains a circadian clock system independent from the central clock located in the suprachiasmatic nucleus (SCN) of the brain. [72] Studies show that circadian clock dysregulation has been linked to obesity. Dysregulation of the circadian clock affects the WNT/β-catenin pathway, malfunction of which is also connected to exudative wet AMD. [73] The gut microbiome regulates circadian rhythm in the brain; [74] but, we provide the first evidence that gut microbiome can also affect the circadian circuit in the retina.

Another important set of genes that are affected in GF mice retina is involved in longevity. Currently, only two genetic factors have been consistently found to contribute to longevity; apolipoprotein E (Apo-E) and FOXO3. [75] Predictably, the analysis of PPI of the downregulated genes in the GF mice retina also highlights FOXO3 as a hub node involved with several other proteins. Aging is the most significant factor contributing to the pathogenesis of retinal degenerative diseases, like AMD. FOXO3 transcription factor is involved in cell survival and apoptosis. PI3K/Akt inhibitors via FOXO3 have demonstrated some efficacy in ameliorating neovascularization in mice models. Gut dysbiosis induced by high-fat diet leads to the inactivation of FOXO3 in the intestine. Our data indicate that the gut microbiome can affect the gene expression of FOXO3 in the mouse retina, but more studies are needed to determine the protein expression and activity of these genes in the retina.

Gut-microbiome is well-known to cause downstream sequelae by mediating both innate and adaptive elements of the immune system. [76] GF mice demonstrate an increase in T helper cell type 2 (Th2) compared to T helper cell type 1 (Th-1) cells and a decrease in T helper 17 cells

(Th-17), T regulatory cells (Tregs), and IL-12 formation. [77] Similarly, the Th17 differentiation pathway in GF mice retina is affected through RC3H1, RC3H2, SMAD7 genes. Both AMD and POAG patients have increased Th1/ Th17 response. [78] Several genes of the cytokine-cytokine receptor interaction are also affected by the gut- microbiome in the retina. Membrane cofactor protein (CD46), a regulator of the alternative pathway of the complement system, is also downregulated in the GF mice retina. CD46 decrease can lead to hyperactivation of the complement system and it has been established that there is a central role of inflammatory pathogenesis in AMD. Retinal pigment epithelial (RPE) cells, the main cell implicated in the AMD pathogenesis, lose their CD46 expression in geographic atrophy even before the appearance of morphologic changes. [79] $Cd46^{-/-}$ knockout mice are used as an experimental animal model who spontaneously develop a dry-type AMD-like phenotype.[80] Our experiment reveals that both innate and adaptive immunity pathways are disrupted in the GF mice retina. Can the microbiome be the unknown link between the sterile inflammation at an immune protected site and AMD is yet to be determined.

Toppgene analysis also provides analysis for the number of diseases related to a particular cohort. The retinal diseases that are involved in the DEGs (p-value-<0.0.5) are shown below (Figure 7).

Several long non-coding RNAs (lncRNA) are differentially expressed in the GF and SPF mice retina (Supplementary Table 1). Long non-coding RNAs (lncRNAs) are increasingly recognized to control cellular functions and regulate transcriptional and translational processes of the neighboring genes. Gut microbiota critically regulates the expression of lncRNAs not only locally in the intestine but also remotely in other metabolic organs, like brown adipose tissue and muscle. [80] The exact role of lncRNA in either the retinal disease is unclear at the moment; however, they have an important function in the retinal ganglion cell differentiation. Our study indicate that gut microbiome could affect retinal functions via regulation of retinal lnc-RNAs expression and possible downstream effects on neighboring genes as seen in other organs.

Nonetheless, the GF mouse studies have some limitations since as host physiological parameters are altered in these mice. The lack of microbiota produces systemic changes in these animals, ranging from an inability to efficiently digest food to an under-developed immune system. Other variations include lengthier intestinal epithelial turnover, lower nutritional requirements, and less body fat despite increased consumption. Moreover, our data is based on RNA-seq alone and no studies of protein expression or activity are performed. RNA-seq studies typically provide the basis for further experiments using specific disease animal models and subsequent human diseases.

Figure 6. AMPK and the genes and pathways perturbed by the gut-microbiome in GF mice. Image made using Biorender.

Gene Symbol	Gene Name
IMPG1	Interphotoreceptor matrix proteoglycan 1
KCNV2	potassium voltage-gated channel modifier subfamily V member 2
MPDZ	multiple PDZ domain crumbs cell polarity complex component
MEF2C	myocyte enhancer factor 2C
PPARGC1A	PPARG coactivator 1 alpha
KL	klotho
AMD1	adenosylmethionine decarboxylase 1
RBP3	retinol binding protein 3
NR4A3	nuclear receptor subfamily 4 group A member 3
CRB1	crumbs cell polarity complex component 1

Gene Symbol	Gene Name
SLC6A6	solute carrier family 6 member 6
SNRNP200	small nuclear ribonucleoprotein U5 subunit 200
RD3	retinal degeneration 3, GUCY2D regulator

Figure 7. DEGs involved in retinal diseases revealed by bioinformatics analysis (Toppgene)

Conclusion

In this study, we explored the retinal transcriptome using high-throughput RNA-seq to investigate the effect of the gut microbiome on whole retinal transcriptome using GF mice to investigate the genes and pathways involved in gut-retina axis.

Our data provide strong evidence for the regulation of important pathways including AMPK, longevity, oxidative stress, MAPK and mitochondrial biogenesis by the gut-microbiome in the retina. Hence, we propose that regulation of biologic retinal pathway via the gut microbiome may be important in retinal diseases. The microbiome can cause variance in gene expression has been demonstrated in other organs; but, this is the first report providing solid evidence of the existence of the gut-retina axis. Even though our data indicates that gut microbiome is a powerful regulator of retinal gene expression, further analyses are needed to elucidate how retina protein expression and cellular functions are modified by the gut-microbiome and their correlation with retinal disease pathogenesis.

References

1. Marchesi JR, Ravel J. The vocabulary of microbiome research: a proposal. Microbiome. 2015 Dec;3(1):31, s40168-015-0094–5.
2. Shreiner AB, Kao JY, Young VB. The gut microbiome in health and in disease: Current Opinion in Gastroenterology. 2015 Jan;31(1):69–75.
3. Kinross JM, Darzi AW, Nicholson JK. Gut microbiome-host interactions in health and disease. Genome Med. 2011;3(3):14.
4. Rowan S, Jiang S, Korem T, Szymanski J, Chang M-L, Szelog J, et al. Involvement of a gut–retina axis in protection against dietary glycemia-induced age-related macular degeneration. Proc Natl Acad Sci USA. 2017 May 30;114(22):E4472–81.
5. Rowan S, Taylor A. The Role of Microbiota in Retinal Disease. In: Ash JD, Anderson RE, LaVail MM, Bowes Rickman C, Hollyfield JG, Grimm C, editors. Retinal Degenerative Diseases (Internet). Cham: Springer International Publishing; 2018 (cited 2020 Jul 31). p. 429–35. (Advances in Experimental Medicine and Biology; vol. 1074). Available from: http://link.springer.com/10.1007/978-3-319-75402-4_53
6. Zárate-Bladés CR, Horai R, Mattapallil MJ, Ajami NJ, Wong M, Petrosino JF, et al. Gut microbiota as a source of a surrogate antigen that triggers autoimmunity in an immune privileged site. Gut Microbes. 2017 Jan 2;8(1):59–66.

7. Baim AD, Movahedan A, Farooq AV, Skondra D. The microbiome and ophthalmic disease. Exp Biol Med (Maywood). 2019 Apr;244(6):419–29.
8. Lin P. Importance of the intestinal microbiota in ocular inflammatory diseases: A review. Clin Experiment Ophthalmol. 2019 Apr;47(3):418–22.
9. Horai R, Zárate-Bladés CR, Dillenburg-Pilla P, et al. Microbiota-Dependent Activation of an Autoreactive T Cell Receptor Provokes Autoimmunity in an Immunologically Privileged Site. Immunity. 2015 Aug;43(2):343-353. DOI: 10.1016/j.immuni.2015.07.014.
10. Orešič M, Seppänen-Laakso T, Yetukuri L, Bäckhed F, Hänninen V. Gut microbiota affects lens and retinal lipid composition. Experimental Eye Research. 2009 Nov;89(5):604–7.
11. Chen H, Cho K-S, Vu THK, Shen C-H, Kaur M, Chen G, et al. Commensal microflora-induced T cell responses mediate progressive neurodegeneration in glaucoma. Nat Commun. 2018 Dec;9(1):3209.
12. Andriessen EM, Wilson AM, Mawambo G, Dejda A, Miloudi K, Sennlaub F, et al. Gut microbiota influences pathological angiogenesis in obesity☐driven choroidal neovascularization. EMBO Mol Med. 2016 Dec;8(12):1366–79.
13. Skondra D, She H, Zambarakji HJ, Connolly E, Michaud N, Chan P, et al. Effects of ApoE Deficiency, Aging and High Fat Diet on Laser-Induced Choroidal Neovascularization and Bruch's Membrane-RPE Interface Morphology. Investigative Ophthalmology & Visual Science. 2007 May 10;48(13):1768–1768.
14. Beli E, Yan Y, Moldovan L, Vieira CP, Gao R, Duan Y, et al. Restructuring of the Gut Microbiome by Intermittent Fasting Prevents Retinopathy and Prolongs Survival in *db/db* Mice. Diabetes. 2018 Sep;67(9):1867–79.
15. Zinkernagel MS, Zysset-Burri DC, Keller I, Berger LE, Leichtle AB, Largiadèr CR, et al. Association of the Intestinal Microbiome with the Development of Neovascular Age-Related Macular Degeneration. Sci Rep. 2017 Feb;7(1):40826.
16. Gong H, Zhang S, Li Q, Zuo C, Gao X, Zheng B, et al. Gut microbiota compositional profile and serum metabolic phenotype in patients with primary open-angle glaucoma. Experimental Eye Research. 2020 Feb;191:107921.
17. Zysset-Burri DC, Keller I, Berger LE, Neyer PJ, Steuer C, Wolf S, et al. Retinal artery occlusion is associated with compositional and functional shifts in the gut microbiome and altered trimethylamine-N-oxide levels. Sci Rep. 2019 Dec;9(1):15303.
18. Skondra D, Rodriguez SH, Sharma A, Gilbert J, Andrews B, Claud EC. The early gut microbiome could protect against severe retinopathy of prematurity [published online ahead of print, 2020 Jul 21]. *JAAPOS*. 2020;S1091-8531(20)30149 doi:10.1016/j.jaapos.2020.03.010 https://doi.org/10.1016/j.jaapos.2020.03.010
19. Morita Y, Jounai K, Sakamoto A, et al. Long-term intake of *Lactobacillus paracasei* KW3110 prevents age-related chronic inflammation and retinal cell loss in physiologically aged mice. *Aging (Albany NY)*. 2018;10(10):2723-2740. doi:10.18632/aging.101583
20. Kim J, Choi SH, Kim YJ, et al. Clinical Effect of IRT-5 Probiotics on Immune Modulation of Autoimmunity or Alloimmunity in the Eye. *Nutrients*. 2017;9(11):1166. Published 2017 Oct 25. doi:10.3390/nu9111166

21. Kennedy EA, King KY, Baldridge MT. Mouse Microbiota Models: Comparing Germ-Free Mice and Antibiotics Treatment as Tools for Modifying Gut Bacteria. Front Physiol. 2018 Oct 31;9:1534.

22. Fritz JV, Desai MS, Shah P, Schneider JG, Wilmes P. From meta-omics to causality: experimental models for human microbiome research. Microbiome. 2013;1(1):14.

23. Schoeb TR, Rahija RJ. Gnotobiotics. In: Laboratory Animal Medicine (Internet). Elsevier; 2015 (cited 2020 Jul 31). p. 1263–96. Available from: https://linkinghub.elsevier.com/retrieve/pii/B9780124095274000262

24. Grover M, Kashyap PC. Germ-free mice as a model to study effect of gut microbiota on host physiology. *Neurogastroenterol Motil*. 2014;26(6):745-748. doi:10.1111/nmo.12366

25. Sommer, F., Bäckhed, F. The gut microbiota — masters of host development and physiology. *Nat Rev Microbiol* **11,** 227–238 (2013). https://doi.org/10.1038/nrmicro2974

26. Knight R, Callewaert C, Marotz C, Hyde ER, Debelius JW, McDonald D, et al. The Microbiome and Human Biology. Annu Rev Genom Hum Genet. 2017 Aug 31;18(1):65–86.

27. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet. 2009 Jan;10(1):57–63.

28. Hooper LV. Molecular Analysis of Commensal Host-Microbial Relationships in the Intestine. Science. 2001 Feb 2;291(5505):881–4.

29. Lahiri S, Kim H, Garcia-Perez I, Reza MM, Martin KA, Kundu P, et al. The gut microbiota influences skeletal muscle mass and function in mice. Sci Transl Med. 2019 Jul 24;11(502):eaan5662.

30. Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, et al. The gut–liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018 Jul;15(7):397–411.

31. National Research Council. Guide for the care and use of Laboratory Animals. 8th ed. Washington, DC: The National Academies Press; 2011.

32. Theriault B, Wang Y, Chen L, Vest A, Bartman C, Alegre ML. Long-term Maintenance of Sterility Following Skin Transplantation in Germ-free Mice. *Transplant Direct*. 2015;1(8):e28. doi:10.1097/TXD.0000000000000539

33. Madduri, R.K.; Sulakhe, D.; Lacinski, L.; Liu, B.; Rodriguez, A.; Chard, K.; Dave, U.J.; Foster, I.T. Experiences building Globus Genomics: A next-generation sequencing analysis service using Galaxy, Globus, and Amazon Web Services. Concurr. Comput. Pract. Exp. 2014, 26, 2266–2279

34. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013 Jan;29(1):15–21.

35. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014 Apr 1;30(7):923–30.

36. Chen Y, Lun ATL, Smyth GK. From reads to genes to pathways: differential expression analysis of RNA-Seq experiments using Rsubread and the edgeR quasi-likelihood pipeline. F1000Res. 2016 Aug 2;5:1438.

37. Frankish A, Diekhans M, Ferreira A-M, Johnson R, Jungreis I, Loveland J, et al. GENCODE reference annotation for the human and mouse genomes. Nucleic Acids Research. 2019 Jan 8;47(D1):D766–73.

38. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010 Jan 1;26(1):139–40.

39. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Research. 2015 Apr 20;43(7):e47–e47.

40. Robinson MD, Oshlack A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol. 2010;11(3):R25.

41. Chen J, Bardes EE, Aronow BJ, Jegga AG. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Research. 2009 Jul 1;37(Web Server):W305–11.

42. Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguez P, et al. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Research. 2011 Jan 1;39(Database):D561–8.

43. Corfield AP. The Interaction of the Gut Microbiota with the Mucus Barrier in Health and Disease in Human. *Microorganisms*. 2018;6(3):78. Published 2018 Aug 2. doi:10.3390/microorganisms6030078

44. Durack J, Lynch SV. The gut microbiome: Relationships with disease and opportunities for therapy. Journal of Experimental Medicine. 2019 Jan 7;216(1):20–40.

45. Garrett WS, Lord GM, Punit S, Lugo-Villarino G, Mazmanian SK, Ito S, et al. Communicable Ulcerative Colitis Induced by T-bet Deficiency in the Innate Immune System. Cell. 2007 Oct;131(1):33–45.

46. Elinav E, Strowig T, Kau AL, Henao-Mejia J, Thaiss CA, Booth CJ, et al. NLRP6 Inflammasome Regulates Colonic Microbial Ecology and Risk for Colitis. Cell. 2011 May;145(5):745–57Roy S, Trinchieri G. Microbiota: a key orchestrator of cancer therapy. Nat Rev Cancer. 2017 May;17(5):271–85.

47. Zitvogel L, Ma Y, Raoult D, Kroemer G, Gajewski TF. The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies. Science. 2018 Mar 23;359(6382):1366–70.

48. Ericsson AC, Franklin CL. Manipulating the Gut Microbiota: Methods and Challenges: Figure 1. ILAR J. 2015 Aug 31;56(2):205–17.

49. Rabot S, Membrez M, Blancher F, Berger B, Moine D, Krause L, et al. High fat diet drives obesity regardless the composition of gut microbiota in mice. Sci Rep. 2016 Sep;6(1):32484.

50. Nakamura YK, Janowitz C, Metea C, Asquith M, Karstens L, Rosenbaum JT, et al. Short chain fatty acids ameliorate immune-mediated uveitis partially by altering migration of lymphocytes from the intestine. Sci Rep. 2017 Dec;7(1):11745.

51. Ouyang H, Mei X, Zhang T, Lu B, Ji L. Ursodeoxycholic acid ameliorates diabetic retinopathy via reducing retinal inflammation and reversing the breakdown of blood-retinal barrier. European Journal of Pharmacology. 2018 Dec;840:20–7.

52. Fernández-Sánchez L, Lax P, Pinilla I, Martín-Nieto J, Cuenca N. Tauroursodeoxycholic Acid Prevents Retinal Degeneration in Transgenic P23H Rats. Invest Ophthalmol Vis Sci. 2011 Jul 1;52(8):4998.

53. Drack AV, Dumitrescu AV, Bhattarai S, Gratie D, Stone EM, Mullins R, et al. TUDCA Slows Retinal Degeneration in Two Different Mouse Models of Retinitis Pigmentosa and

Prevents Obesity in Bardet-Biedl Syndrome Type 1 Mice. Invest Ophthalmol Vis Sci. 2012 Jan 5;53(1):100.

54. Mantopoulos D, Murakami Y, Comander J, Thanos A, Roh M, Miller JW, et al. Tauroursodeoxycholic Acid (TUDCA) Protects Photoreceptors from Cell Death after Experimental Retinal Detachment. Koch K-W, editor. PLoS ONE. 2011 Sep 22;6(9):e24245.

55. Gaspar JM, Martins A, Cruz R, Rodrigues CMP, Ambrósio AF, Santiago AR. Tauroursodeoxycholic acid protects retinal neural cells from cell death induced by prolonged exposure to elevated glucose. Neuroscience. 2013 Dec;253:380–8.

56. Dalile B, Van Oudenhove L, Vervliet B, Verbeke K. The role of short-chain fatty acids in microbiota–gut–brain communication. Nat Rev Gastroenterol Hepatol. 2019 Aug;16(8):461–78.

57. Zhang, M., Jiang, N., Chu, Y., Postnikova, O., Varghese, R., Horvath, A., Cheema, A. K., & Golestaneh, N. (2020). Dysregulated metabolic pathways in age-related macular degeneration. *Scientific reports*, *10*(1), 2464. https://doi.org/10.1038/s41598-020-59244-4

58. Zhou J, Chen F, Yan A & Xia X(2019) Role of mammalian target of rapamycin in regulating HIF-1α and vascular endothelial growth factor signals in glaucoma, Archives of Physiology and Biochemistry, DOI: 10.1080/13813455.2019.1609996

59. Reihill JA, Ewart MA, Hardie DG, Salt IP. AMP-activated protein kinase mediates VEGF-stimulated endothelial NO production. *Biochem Biophys Res Commun*. 2007;354(4):1084-1088. doi:10.1016/j.bbrc.2007.01.110

60. Noureldein M, Eid A, Gut microbiota and mTOR signaling: Insight on a new pathophysiological interaction. Microbial Pathogenesis Volume 118, May 2018, Pages 98-104. https://doi.org/10.1016/j.micpath.2018.03.021

61. Morris G, Berk M, Carvalho A, Caso J, Sanz Y, Maes M. The Role of Microbiota and Intestinal Permeability in the Pathophysiology of Autoimmune and Neuroimmune Processes with an Emphasis on Inflammatory Bowel Disease Type 1 Diabetes and Chronic Fatigue Syndrome. CPD. 2016 Dec 14;22(40):6058–75.

62. Fish JE, Cantu Gutierrez M, Dang LT, Khyzha N, Chen Z, Veitch S, et al. Dynamic regulation of VEGF-inducible genes by an ERK/ERG/p300 transcriptional network. Development. 2017 Jul 1;144(13):2428–44.

63. Vinores SA, Xiao W-H, Aslam S, Shen J, Oshima Y, Nambu H, et al. Implication of the hypoxia response element of the vegf promoter in mouse models of retinal and choroidal neovascularization, but not retinal vascular development. J Cell Physiol. 2006 Mar;206(3):749–58.

64. Kwak N, Okamoto N, Wood JM, Campochiaro PA. VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2000 Sep;41(10):3158–64.

65. Heckenlively JR, Hawes NL, Friedlander M, Nusinowitz S, Hurd R, Davisson M, et al. Mouse model of subretinal neovascularization with choroidal anastomosis: retina. 2003 Aug;23(4):518–22.

66. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1996 Apr;37(5):855–68.

67. Bhutto IA, McLeod DS, Hasegawa T, Kim SY, Merges C, Tong P, et al. Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. Experimental Eye Research. 2006 Jan;82(1):99–110.

68. Tong J-P, Chan W-M, Liu DTL, Lai TYY, Choy K-W, Pang C-P, et al. Aqueous Humor Levels of Vascular Endothelial Growth Factor and Pigment Epithelium–Derived Factor in Polypoidal Choroidal Vasculopathy and Choroidal Neovascularization. American Journal of Ophthalmology. 2006 Mar;141(3):456–62.

69. Kyosseva SV. Targeting MAPK Signaling in Age-Related Macular Degeneration. Ophthalmol Eye Dis. 2016 Jan;8:OED.S32200.

70. Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. The Lancet Oncology. 2012 Aug;13(8):773–81.

71. Ma Y, Zhao Q, Shao Y, Cao M-Z, Zhao M, Wang D. Melatonin inhibits the inflammation and apoptosis in rats with diabetic retinopathy via MAPK pathway. European Review for Medical and Pharmacological Sciences. 2019 Aug;23(3 Suppl):1–8.

72. Paulose JK, Wright JM, Patel AG, Cassone VM. Human Gut Bacteria Are Sensitive to Melatonin and Express Endogenous Circadian Rhythmicity. Yamazaki S, editor. PLoS ONE. 2016 Jan 11;11(1):e0146643.

73. Su Terman J, Remeˊ CE, Terman M. Rod outer segment disk shedding in rats with lesions of the suprachiasmatic nucleus. Brain Research. 1993 Mar;605(2):256–64.

74. Vallée A, Lecarpentier Y, Vallée R, Guillevin R, Vallée J-N. Circadian Rhythms in Exudative Age-Related Macular Degeneration: The Key Role of the Canonical WNT/β-Catenin Pathway. IJMS. 2020 Jan 27;21(3):820.

75. Leone V, Gibbons SM, Martinez K, Hutchison AL, Huang EY, Cham CM, et al. Effects of Diurnal Variation of Gut Microbes and High-Fat Feeding on Host Circadian Clock Function and Metabolism. Cell Host & Microbe. 2015 May;17(5):681–9.

76. Mortzfeld BM, Taubenheim J, Fraune S, Klimovich AV, Bosch TCG. Stem Cell Transcription Factor FoxO Controls Microbiome Resilience in Hydra. Front Microbiol. 2018 Apr 3;9:629.

77. Ren Y, Qi Y, Su X. Th17 cells in glaucoma patients promote Ig production in IL 17A and IL 21 dependent manner. Clin Exp Pharmacol Physiol. 2019 Oct;46(10):875–82.

78. Hrncir T, Stepankova R, Kozakova H, Hudcovic T, Tlaskalova-Hogenova H. Gut microbiota and lipopolysaccharide content of the diet influence development of regulatory T cells: studies in germ-free mice. BMC Immunol. 2008;9(1):65.

79. Chen J, Wang W, Li Q. Increased Th1/Th17 Responses Contribute to Low-Grade Inflammation in Age-Related Macular Degeneration. Cell Physiol Biochem. 2017;44(1):357–67.

80. Vogt SD, Curcio CA, Wang L, Li C-M, McGwin G, Medeiros NE, et al. Retinal pigment epithelial expression of complement regulator CD46 is altered early in the course of geographic atrophy. Experimental Eye Research. 2011 Oct;93(4):413–23.

81. Lyzogubov VV, Bora PS, Wu X, Horn LE, de Roque R, Rudolf XV, et al. The Complement Regulatory Protein CD46 Deficient Mouse Spontaneously Develops Dry-Type Age-Related

Macular Degeneration–Like Phenotype. The American Journal of Pathology. 2016 Aug;186(8):2088–104.

82. Dempsey J, Zhang A, Cui JY. Coordinate regulation of long non-coding RNAs and protein-coding genes in germ-free mice. BMC Genomics. 2018 Dec;19(1):834.

83. Franklin CL, Ericsson AC. Microbiota and reproducibility of rodent models. Lab Anim. 2017 Apr;46(4):114–22.